Hi Fivecent,
The Open Label BioMuse study are patients that are long term sufferers. You are right in saying Alterity was very specific in what Patients were allowed to participate. They were very carefully chosen. If the result's from that study prove to be a conclusive event, then the new sufferers from MSA in the double blind placebo study should be a foregone conclusion. The long-term sufferer's in my opinion ares the harder of the two to conquer. The results from the first trial can really catapult the SP if they meet or exceed market expectations.
Stockman
Ann: Alterity Parkinson's and MSA Data Featured at AAN Meeting, page-16
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.001(20.0%) |
Mkt cap ! $31.47M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.6¢ | 0.5¢ | $3.796K | 659.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 45 | 37913342 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 18720215 | 20 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.6¢ |
Change
0.001 ( 10.0 %) |
||||
| Open | High | Low | Volume | ||
| 0.5¢ | 0.6¢ | 0.5¢ | 1109600 | ||
| Last updated 15.59pm 21/05/2024 ? | |||||
| ATH (ASX) Chart |